Cargando…

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Endoglin, or CD105, is a cell membrane glycoprotein that is overexpressed on proliferating endothelial cells (EC), including those found in malignancies and choroidal neovascularization. Endoglin mediates the transition from quiescent endothelium, characterized by the relatively dominant state of Sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yingmiao, Tian, Hongyu, Blobe, Gerard C., Theuer, Charles P., Hurwitz, Herbert I., Nixon, Andrew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169868/ https://www.ncbi.nlm.nih.gov/pubmed/24994097 http://dx.doi.org/10.1007/s10637-014-0129-y

Ejemplares similares

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
por: Tripska, Katarina, et al.
Publicado: (2022)

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
por: Brossa, Alessia, et al.
Publicado: (2018)

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
por: Mehta, C R, et al.
Publicado: (2019)

In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2014)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
por: Galanis, Evanthia, et al.
Publicado: (2022)

Abstract 25 Cord Blood Mononuclear Cells and Cord Blood Plasma Alter Human Cardiac Endothelial Cell Angiogenic Sprouting and Growth In Vitro
por: Chuang, Angela, et al.
Publicado: (2023)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
por: Liu, Yingmiao, et al.
Publicado: (2013)

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
por: Uronis, Hope E, et al.
Publicado: (2013)

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors
por: Alshaker, Heba, et al.
Publicado: (2018)

CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo
por: Koch, Manuel, et al.
Publicado: (2010)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry
por: Wirtz, Ralph M., et al.
Publicado: (2016)

Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists
por: Łupicka-Słowik, Agnieszka, et al.
Publicado: (2020)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007)

Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)

Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
por: Trendowski, Matthew, et al.
Publicado: (2015)

Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer
por: Korobeynikov, Vladislav, et al.
Publicado: (2019)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
por: Tiainen, Satu, et al.
Publicado: (2019)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
por: Yan, S. Betty, et al.
Publicado: (2017)

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014)

Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
por: van Gelder, Michel, et al.
Publicado: (2016)

Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation
por: Phyu, Su Myat, et al.
Publicado: (2018)

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
por: Collery, Philippe, et al.
Publicado: (2015)

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine
por: Bijnsdorp, Irene V., et al.
Publicado: (2009)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
por: Weigman, Victor J., et al.
Publicado: (2011)

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
por: Pfefferle, Adam D., et al.
Publicado: (2015)

FOXA1 is a determinant of drug resistance in breast cancer cells
por: Kumar, Uttom, et al.
Publicado: (2021)

Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
por: Bardowell, Sabrina A., et al.
Publicado: (2013)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

The molecular diversity of Luminal A breast tumors
por: Ciriello, Giovanni, et al.
Publicado: (2013)

Disruption of hippocampal synaptic transmission and long‐term potentiation by psychoactive synthetic cannabinoid ‘Spice’ compounds: comparison with Δ(9)‐tetrahydrocannabinol
por: Hoffman, Alexander F., et al.
Publicado: (2016)

MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis
por: Yang, Fan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_27osdplia2696j28vv2vcr492g